Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Sponsor: Octapharma
Listed as NCT01888484, this PHASE3 trial focuses on Primary Immune Deficiency Disorder and remains completed. Sponsored by Octapharma, it has been updated 15 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 10 earlier versions
-
Sep 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Octapharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bialystok, Poland , Birmingham, United States , Bratislava, Slovakia , Brno, Czechia , Budapest, Hungary , Centennial, United States , Edmonton, Canada , Frisco, United States , Irvine, United States , Košice, Slovakia and 13 more locations